Principal Financial Group Inc. Has $5.78 Million Holdings in EXACT Sciences Co. (EXAS)
Principal Financial Group Inc. reduced its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 2.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 122,661 shares of the medical research company’s stock after selling 3,436 shares during the quarter. Principal Financial Group Inc. owned approximately 0.10% of EXACT Sciences worth $5,780,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Aperio Group LLC acquired a new position in EXACT Sciences during the 2nd quarter worth about $252,000. Russell Investments Group Ltd. lifted its stake in EXACT Sciences by 46.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 175,026 shares of the medical research company’s stock worth $6,190,000 after acquiring an additional 55,544 shares in the last quarter. Sei Investments Co. acquired a new position in EXACT Sciences during the 2nd quarter worth about $1,548,000. IFP Advisors Inc raised its position in EXACT Sciences by 315.5% in the 2nd quarter. IFP Advisors Inc now owns 13,850 shares of the medical research company’s stock valued at $490,000 after purchasing an additional 10,517 shares in the last quarter. Finally, Pioneer Investment Management Inc. raised its position in EXACT Sciences by 579.7% in the 2nd quarter. Pioneer Investment Management Inc. now owns 425,242 shares of the medical research company’s stock valued at $15,041,000 after purchasing an additional 362,683 shares in the last quarter. Institutional investors own 82.39% of the company’s stock.
In other EXACT Sciences news, insider Kevin T. Conroy sold 121,849 shares of EXACT Sciences stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $53.45, for a total value of $6,512,829.05. Following the transaction, the insider now directly owns 951,901 shares in the company, valued at approximately $50,879,108.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Graham Peter Lidgard sold 45,770 shares of EXACT Sciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $58.27, for a total value of $2,667,017.90. Following the completion of the transaction, the insider now owns 237,820 shares in the company, valued at $13,857,771.40. The disclosure for this sale can be found here. Insiders have sold a total of 595,396 shares of company stock worth $32,953,769 in the last 90 days. 4.00% of the stock is currently owned by company insiders.
A number of research firms have issued reports on EXAS. BidaskClub lowered EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Bank of America increased their price target on EXACT Sciences from $58.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, November 29th. Leerink Swann reaffirmed an “outperform” rating and issued a $67.00 price target (up previously from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Robert W. Baird lowered EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price target on the stock. in a research report on Monday, November 13th. Finally, Zacks Investment Research lowered EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $50.58.
EXACT Sciences Co. (NASDAQ EXAS) opened at $53.83 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. EXACT Sciences Co. has a 12 month low of $13.05 and a 12 month high of $63.60.
EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. The firm had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm’s quarterly revenue was up 158.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.36) EPS. analysts predict that EXACT Sciences Co. will post -1.12 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Principal Financial Group Inc. Has $5.78 Million Holdings in EXACT Sciences Co. (EXAS)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/principal-financial-group-inc-has-5-78-million-holdings-in-exact-sciences-co-exas/1753035.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.